Hyperpolarized 13C,15N2-urea

Phase 2Small molecule

IIvan de Kouchkovsky, MD

Hyperpolarized 13C,15N2-urea is one of 34 small molecule programs targeting MRI Scan. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MRI ScanActive, not recruiting

Prostate CancerRecruiting

MRI ScanPhase 2

Active, not recruiting

Prostate CancerPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

7 2

Antiandrogen Therapy

UUniversity of Washington

Phase 3

10 3

AAA817

Novartis

Phase 3

1 4

Gallium Ga 68 Gozetotide

MMayo Clinic

Phase 3

3 5

Androgen Deprivation Treatment

MMedical University of Vienna

Phase 3

1 6

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

2 7

Trexall

Jazz Pharmaceuticals

Preclinical

—8

Hyperpolarized 13C,15N2-urea

IIvan de Kouchkovsky, MD

Phase 2

1 9

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 10

Duragesic

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

MRI Scan

NCT04258462

Phase 1Recruiting

Prostate Cancer

NCT02526368

Clinical

Trials by Indication[1]

MRI Scan1 trial

Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors

Active, not recruiting·ZZhen Wang, MD·Phase 2·NCT04258462·54 enrolled

Prostate Cancer1 trial

Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer

Recruiting·IIvan de Kouchkovsky, MD·Phase 1·NCT02526368·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Hyperpolarized 13C,15N2-urea. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyperpolarized 13C,15N2-urea compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyperpolarized 13C,15N2-urea. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ivan de Kouchkovsky, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIvan de Kouchkovsky, MD

Hyperpolarized 13C,15N2-urea

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

MRI Scan1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News